Stocks · News reference
Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
- SEC Filing